Data from EMA (European Medicines Agency) - Curated by Marshall Pearce - Last updated 13 December 2017

Indication(s)

Cerdelga is indicated for the long-term treatment of adult patients with Gaucher disease type 1 (GD1), who are CYP2D6 poor metabolisers (PMs), intermediate metabolisers (IMs) or extensive metabolisers (EMs).

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Obesity

Obesity

Learn about the complex factors influencing development of obesity.

+ 4 more

Hyperammonaemia

Hyperammonaemia

Hyperammonaemia can result in serious neurological damage or death. Could you recognise the signs and symptoms?

+ 2 more

ALP Lab Assessment

ALP Lab Assessment

Discover and overview of hypophosphatasia and details required to facilitate the timely and accurate detection of low alkaline phosphatase.

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/003724
Orphan designation Yes
Date First Approved 19-01-2015
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Genzyme Europe BV
Warnings This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions